Citations

Clear

247 citation(s) found for "Chapman, J-AW".

Abstract A049: Spatially resolved microenvironment profiling reveals distinct follicular lymphoma archetypes
Thakkar, Bijal, Wilson, Ashley , Henderson, Jared, Ayers, Amy, Borgschatz, Sara, Harkins, R. Andrew, Lakra, Priya , Cohen, Jonathon B., Russler-Germain, David, Vega, Francisco, Chapman, J., Inghirami, Giorgio, Lossos, Izidore S. , Koff, Jean L., Nze, Chijioke, Martin, Peter, Syrbu, Sergei, Vij, Kiran, Flowers, Christopher R. , Novak, Anne J., Chihara, Dai, Sakata-Yanagimoto, Mamiko, Tobin, Joshua, Green, M, Abe, Yoshiaki , Kizhakeyil, Atish , Feldman, Andrew L. , Henderson, Jared M. , Ayers, Amy , Harkins, R. Andrew , Kaji, Daisuke , Cohen, Jonathon B. , Mou, Eric , Inghirami, Giorgio , Casulo, Carla , Koff, Jean L. , Nze, Chijioke , Syrbu, Sergei , Jaye, David L. , Cerhan, James R. , Novak, Anne J. , Burack, Richard , Sakata‐Yanagimoto, Mamiko , Tobin, Joshua W.D. , Li, Xubin

Mayo Clinic

Blood Cancer Discovery | June 24, 2026 | Volume: 7 | Issue: 3_Supplement | Pages: A049-A049

10.1158/2643-3249.lymphoma26-a049 Get It

Abstract Recent single-cell transcriptomic studies of follicular lymphoma (FL) have revealed heterogeneity among malignant B (MB) cells and selected components of the tumor microenvironment (TME), but have been constrained by relatively small sample sizes and a lack of spatial context. We performed comprehensive cellular profiling and spatial dissection of over five million cells by integrating single-nucleus RNA sequencing (snRNA-seq) from 182 samples (FL, n = 167; control, n = 15) with single-cell spatial transcriptomics (ST) from 386 samples (FL, n = 365; control, n = 21). After stringent quality control, 1,289,073 and 3,968,427 cells from snRNA-seq and ST data, respectively, were analyzed. Unsupervised clustering of snRNA-seq data identified 58 TME cell subtypes. To extend this classification to the ST dataset, we integrated snRNA-seq and ST data by co-embedding them into a shared principal component space, enabling robust batch correction and cell-type label transfer across modalities. Using this supervised annotation framework, ST data recapitulated 54 TME cell subtypes. MB, proliferating MB (MBprolif), and healthy B (HB) cells were classified using sample-level unsupervised clustering in ST. Macrophages exhibited previously uncharacterized heterogeneity in transcriptomic profiles and spatial distribution. We identified CXCL13-expressing macrophage subtypes with high intra- and peri-follicular abundance, termed follicular macrophages (FMs). Non-negative matrix factorization of intrafollicular cell fractions identified five TME archetypes: FM, follicular stroma, two follicular T, and HB archetypes. The FM archetype was enriched for intrafollicular macrophages, including FMs, and showed a significantly higher proportion of grade 3A/3B cases (53.4%) compared to other archetypes (≤16.5%). It was also associated with a higher frequency of high tumor burden requiring treatment initiation rather than a watch-and-wait (WW) approach. Among patients managed by WW, those with the FM archetype showed significantly shorter event-free survival (EFS) compared to those with non-FM archetypes, whereas this association was not observed among treated patients. The percentage of intrafollicular macrophages (IFMP) showed excellent predictive performance for the FM archetype (area under the curve: 0.90). IFMP calculated in a published multiplex spatial protein imaging dataset from an independent cohort of 242 FL patients validated the associations between high IFMP and both pathology grade 3A/3B and shorter EFS in WW patients. Consistently, spatial neighborhood and cell–cell communication analyses revealed co-localization of FMs and MBprolif cells, forming a distinct niche with activated signaling mediated by FM-derived CXCL13, APRIL, and BAFF. Our integrative multi-modal analysis defines previously unrecognized cellular heterogeneity and spatial architecture in FL and highlights macrophage-enriched follicular ecosystems associated with aggressive clinicopathological features, providing a framework for improved biological understanding and patient management. Citation Format: Yoshiaki Abe, Bijal Thakkar, Atish Kizhakeyil, Ashley Wilson, Andrew L. Feldman, Jared Henderson, Amy Ayers, Sara Borgschatz, R. Andrew Harkins, Priya Lakra, Daisuke Kaji, Jonathon B. Cohen, David Russler-Germain, Eric Mou, Francisco Vega, Jennifer Chapman, Giorgio Inghirami, Carla Casulo, Izidore S. Lossos, Jean L. Koff, Chijioke Nze, Peter Martin, Sergei Syrbu, Kiran Vij, David L. Jaye, James R. Cerhan, Christopher R. Flowers, Anne J. Novak, Richard Burack, Dai Chihara, Mamiko Sakata-Yanagimoto, Joshua Tobin, Xubin Li, Michael R. Green. Spatially resolved microenvironment profiling reveals distinct follicular lymphoma archetypes [abstract]. In: Proceedings of the Fifth AACR International Meeting on Advances in Malignant Lymphoma: From Discovery to Clinical Impact; 2026 Jun 24-27; Philadelphia, PA. Philadelphia (PA): AACR; Blood Cancer Discov 2026;7(3_Suppl):Abstract nr A049.
Real World Analysis of Machine Perfusion in Liver Transplantation – An International Cohort Study
Pfister, M, Eden, J, Rasel, H, Abbassi, F, Botea, F, Buchholz, B, Camagni, S, Chapman, W, Cillo, U, Cimeno, A, Compagnon, P, Croome, K, Carlis, R de, Diogo, D, Dondossola, D, Fung, J, Fronek, J, Garcia, C, Györi, G, Koliogiannis, D, Lam, H D, Lurje, G, Magistri, P, Monbaliu, D, Patel, M, Patrono, D, Porte, R, Ravaioli, M, Rayar, M, Satish, S, Schlegel, A, Shapiro, J, Sörensen, G, Vaccharajani, N, Vagefi, P, Pinna, A, Dutkowski, P, Meijer, V de, Clavien, P A, Pfister, Matthias , Eden, Janina , Rasel, Hannah, Abbassi, Fariba , Botea, Florin , Buchholz, Bettina M. , Camagni, Stefania , Cimeno, Arielle , Compagnon, Philippe , Croome, Kristopher P. , Carlis, Riccardo De , Diogo, D. , Dondossola, Daniele Eliseo , Froněk, Jiří , Györi, Georg, Koliogiannis, Dionysios , Lam, Hwai‐Ding , Lurje, Georg , Magistri, Paolo , Monbaliu, Diethard , Patel, Madhukar S. , Patrono, Damiano , Ravaioli, Matteo , Rayar, Michel , Schlegel, Andrea , Shapiro, A. M. James , Sörensen, Gustaf, Vaccharajani, N., Vagefi, Parsia A. , Dutkowski, Philipp , Meijer, Vincent Erwin de

Mayo Clinic

British Journal of Surgery | June 3, 2026 | Volume: 113 | Issue: Supplement_5 | Pages: No page available

10.1093/bjs/znag055.059 Get It

Abstract Background Machine perfusion represents the most significant breakthrough in liver transplantation (LT) since the discovery of cyclosporin. Yet, the optimal perfusion strategy remains unsettled. Randomized trials demonstrate that hypothermic oxygenated perfusion (HOPE) improves graft survival and function and reduces ischemic cholangiopathy, whereas normothermic machine perfusion (NMP) decreases post-transplant injury. Real-world comparisons are lacking and challenging due to heterogeneity in donor-recipient risk profiles and regional differences. Aims To compare real-world outcomes of HOPE and NMP in LT. Methods We analyzed consecutive NMP-preserved LTs from seven North American centers between 2021 and 2024. We compared NMP to the European HOPE-REAL cohort, comprising HOPE-treated LTs from 22 centers between 2012 and 2021. Analyses were stratifyied by graft type and risk category and adjusted for donor age, donor risk index, and balance of risk score using entropy balancing. Results A total of 470 NMP and 1202 HOPE-treated grafts were analyzed, revealing major differences in risk profiles (Figure 1). In NMP, death-censored graft survivals at 1, 2, and 3 years were >95% in donation after brain death (DBD) and >94% in donation after circulatory death (DCD) grafts. Comparable outcomes were observed in the HOPE cohort with >93%, in DBD, and >87% in DCD after up to 3 years, despite significantly higher donor age and longer functional warm ischemia in the HOPE DCD cohort (Figure 2). After risk adjustment, death-censored graft survival remained similar between both modalities (Table 1). Non-anastomotic biliary stricture rates after DCD-LT were comparable (8.5% vs. 12.4%), independent of whether continuous or end-ischemic NMP was performed. Conclusion This first transatlantic real-world report demonstrates excellent outcomes with both NMP and HOPE despite higher graft risk in Europe. Machine perfusion is the new standard of care in LT, while further understanding is needed regarding the distinct benefits of each modality across risk profiles.Figure 1.Graft risk in NMP and HOPE stratified by graft type. Benchmark case was defined as primary transplant with MELD <20 and BAR score <9, extended criteria as either BMI >30kg/m2, donor age >65 years, CIT >12h. DCD grafts were categorized as definedFor image description, please refer to the figure legend and surrounding text. Figure 2.Death-censored graft survival in liver transplantation following NMP and HOPE stratified by graft type. Abbreviations: NMP (Normothermic Machine Perfusion), HOPE (Hypothermic Oxygenated Perfusion), DBD (Donation after Brain Death), DCD (Donation after circulatory death)For image description, please refer to the figure legend and surrounding text. Table 1.Risk-adjusted comparison of death-censored graft survival between NMP and HOPE.For image description, please refer to the figure legend and surrounding text.
Portal-Venous Hypothermic Oxygenated Perfusion for Liver Transplant
Reich, David J. , Mao, Shennen, Satish, Sangeeta , Nassar, Ahmed, Rizzari, Michael, Al‐Adra, David , Woloszyn, Jakub, Doyle, M.B. Majella, Bohórquez, Humberto, Mihaylov, Plamen, Saharia, Ashish, Wehrle, Chase J., Miller, Charles, Axelrod, David, An, Langnas, Melcher, Marc L., Akoad, Mohamed, Ghobrial, R. Mark , Kubal, Chandrashekhar, Roll, Garrett, Cohen, Ari, Chapman, William C., Pinna, Antonio, Vera, Michael de , Florman, Sander, Foley, David P. , Abouljoud, Marwan, Quintini, Cristiano , Hashimoto, Koji, Croome, Kristopher, Taner, C. Burin, Schlegel, Andrea, Schlegel, Andrea , Taner, C. Burcin , Schlegel, Andrea , Nassar, Ahmed , Rizzari, Michael D. , DiNorcia, Joseph , Bohorquez, Humberto E. , Mihaylov, Plamen , Saharia, A., Merani, Shaheed , Wehrle, Chase J. , Miller, Charles , Axelrod, David A. , Langnas, Alan N. , Melcher, Marc L. , Akoad, Mohamed Elhassan , Kubal, Chandrashekhar A. , Roll, Garrett Richard , Chapman, William C. , Pinna, Antonio D., Vera, Michael E. de , Abouljoud, Marwan , Hashimoto, Koji, Croome, Kristopher P.

Mayo Clinic

JAMA Surgery | May 27, 2026 | Volume: 161 | Issue: 7 | Pages: 691

10.1001/jamasurg.2026.1604 | PMID 42201712 Get It

Importance Ischemia-reperfusion injury contributes to graft dysfunction after liver transplant. Hypothermic oxygenated perfusion (HOPE) has been shown to improve liver function, but its benefit in extended criteria donors in a US population remains unclear. Objective To assess whether back-to-base portal-venous HOPE impacts outcomes after liver transplant in the US. Design, Setting, and Participants The Bridge to HOPE Trial is a multicenter, randomized, open-label trial with 1-year follow-up. The study took place at 15 US liver transplant centers and patients were enrolled between January 2021 and May 2023. Central assessment of complications and cholangiograms for nonanastomotic biliary strictures (NAS) was blinded to treatment arm. Participants included 219 recipients of extended-criteria donor livers after brain death (DBD) and after circulatory death (DCD) who were randomized 1:1 to HOPE after static cold storage (SCS) (n = 109) or SCS only (n = 110). Randomization was performed after liver inspection and acceptance for transplant. Data were analyzed from December 2024 to July 2025. Intervention After SCS and transport, livers underwent portal-venous HOPE until implant, using the VitaSmart HOPE System. Main Outcomes and Measures The primary efficacy end point was early allograft dysfunction (EAD). Other main outcomes included model for early allograft function (MEAF) score, hospital length of stay (LOS), patient and graft survival, and biliary complications. Additional post hoc analyses were performed. Results Overall, 219 patients (82 female [37.4%] and 137 male[62.6%]) were included (DCD, 57 of 219 [26%]) with 97% (212 of 219) completing 12-month follow-up. EAD incidence was 20.2% (22 of 109) with HOPE vs 37.3% (41 of 110) with SCS (rate difference, −17.1%; 95% CI, −27.2 to −7.0; noninferiority P < .001; superiority P = .005). HOPE treatment led to significantly lower MEAF mean (SD) scores (HOPE group, 4.28 [1.75]; control group, 4.82 [1.85]; mean difference, −0.54; 95% CI, −1.02 to −0.06; P = .03) and shorter median LOS (hazard ratio, 1.32; 95% CI, 1.01-1.73; P = .04). NAS on imaging and 1-year survivals were comparable between groups (patients: HOPE group, 106 of 109 [97.2%] vs SCS, 106 of 110 [96.4%]; graft: HOPE group, 104 of 109 [95.4%] vs SCS, 102 of 110 [92.7%]). Post hoc analyses showed numerically less graft loss due to NAS after HOPE (4 vs 1) and less major complications (Clavien-Dindo classification ≥IIIa) per patient, respectively. Conclusions and Relevance Back-to-base portal-venous HOPE was compared with SCS alone for extended risk DBD and DCD livers. The HOPE approach was safe and associated with reduced EAD, MEAF score, and LOS. These findings support the use of HOPE as a pragmatic strategy to improve early posttransplant outcomes. Trial Registration ClinicalTrials.gov Identifier: NCT05045794 .
Pregnancy and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease
Lapierre, Stephanie , You, Zhiying , Gitomer, Berenice Y. , Chapman, Arlene B. , Harris, Peter, Perrone, Ronald D. , Rahbari-Oskoui, Frederic F. , Chonchol, Michel, Nowak, Kristen L. , Harris, Peter C. , Lapierre-Nguyen, Stephanie , Gitomer, Berenice Y , Abebe, Kaleab Z , Chapman, Arlene B. , Harris, Peter C , Torres, Vicente E , Rahbari-Oskoui, Frederic F , Torres, Vicente E , Nowak, Kristen L , You, Zhiying , Chonchol, Michel

Mayo Clinic

Journal of the American Society of Nephrology | May 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1681/asn.0000001131 | PMID 42149684 Get It

Key Points In an observational cohort of mostly non-Hispanic White women, pregnancy was not associated with later-life accelerated kidney function decline. Pregnancy occurring during the HALT Progression of Polycystic Kidney Disease (HALT-PKD) trial was not associated with kidney disease progression relative to women who did not become pregnant. Prior evidence indicates that adverse pregnancy outcomes may be involved in autosomal dominant polycystic kidney disease progression; pregnant women should be closely monitored. Background Data are conflicting regarding whether pregnancy influences disease progression in women with autosomal dominant polycystic kidney disease (ADPKD). This study examined whether pregnancy or number of pregnancies was associated with kidney disease progression in women with ADPKD. Methods Women with early- (study A) and late-stage (study B) ADPKD from the HALT Progression of Polycystic Kidney Disease (HALT-PKD) trial were included to examine the association between self-reported number of pregnancies (categorical predictor: no pregnancy versus 1–2 pregnancies and ≥3 pregnancies), annual slope of eGFR, annual percent change in total kidney volume (%ΔTKV), and a composite outcome (kidney failure, 50% decline in eGFR, or death) using multivariable linear regression and Cox proportional hazard models. In addition, women who became pregnant, had full-term pregnancies, and available data during study participation ( n =13) were propensity matched (1:4) to women who were not pregnant during study participation, and a mixed model was applied to determine the association of pregnancy with eGFR slope and %ΔTKV. Results Across all analyses, 455 women with a median age of 45 (interquartile range, 38–50) years and eGFR of 69±25 ml/min per 1.73 m 2 at baseline were included. One hundred ninety-nine women had 1–2 pregnancies, and 165 women had ≥3 pregnancies. There was no association of 1–2 pregnancies or ≥3 pregnancies (versus no pregnancies) with eGFR slope ( β -estimate [95% confidence interval (CI)]; 1–2 pregnancies: 0.22 [−0.44 to 0.89]; ≥3 pregnancies: −0.46 [−1.16 to 0.25]), %ΔTKV ( β -estimate [95% CI]; 1–2 pregnancies: 0.92 [−0.34 to 2.17]; ≥3 pregnancies: 0.69 [−0.67 to 2.04]), or time to composite outcome (hazard ratio [95% CI]; 1–2 pregnancies: 1.04 [0.56 to 1.93]; ≥3 pregnancies: 1.48 [0.78 to 2.77]) in adjusted models. Moreover, there was no difference in annual eGFR slope ( β -estimate: −0.14 [95% CI, −2.72 to 2.44]) and %ΔTKV ( β -estimate: 0.04 [95% CI, −3.74 to 3.82]) in women who became pregnant matched to women who did not became pregnant during their participation in the study. Conclusions Pregnancy was not associated with ADPKD progression among women with early- and late-stage ADPKD enrolled in the HALT-PKD trial.
Lynch Syndrome in the General Population: Clinical Phenotype of PMS2 Pathogenic Variants
Barrett, Kelly M. Schiabor , Hajek, Catherine, Lu, James T. , Lynch, Kate , Sturm, Amy C., Haldeman‐Englert, Chad , Stoller, Douglas , Chapman, Christopher N., Chahal, C. Anwar A. , Judge, Daniel P., Olson, Douglas A., Lee, William , Cirulli, Elizabeth T., Chahal, Choudhary Anwar A , Hajek, Catherine A. , Lynch, Kate, Senter, Leigha , Sturm, Amy C. , Stoller, Douglas A. , Judge, Daniel P. , Olson, Douglas A., Grzymski, Joseph J. , Cirulli, Elizabeth T. , Bolze, Alexandre

Mayo Clinic

JCO Oncology Advances | May 12, 2026 | Volume: 3 | Issue: 2 | Pages: No page available

10.1200/oa-25-00075 Get It

PURPOSE The Lynch syndrome (LS) genes, MLH1 , MSH2 , MSH6 , and PMS2 , are considered to be some of the highest-priority genes to be tested for population genomic screening, with the aim to prevent and detect cancers early in those with a higher risk for such diagnoses. The objective of this study was to determine the risk of cancer associated with pathogenic variants in MLH1 , MSH2 , MSH6 , or PMS2 in the general population to build evidence-based guidelines for population genomic screening METHODS This retrospective case-control study uses Helix Research Network data from 230,159 participants across nine US health systems. Variant interpretation was performed following the American College of Medical Genetics and Association for Molecular Pathology guidelines. Clinical diagnoses were identified from electronic health records and claims data for 11 cancer types associated with LS, including colorectal and endometrial cancers. RESULTS Individuals with pathogenic variants in MLH1 , MSH2 , and MSH6 showed substantial risk for LS-related cancers compared with those without pathogenic variants. Conversely, individuals with pathogenic variants in PMS2 had no increase in risk for all 11 LS-associated cancers with hazard ratio (HR) of 1.0 (95% CI, 0.6 to 1.8) compared with those without a pathogenic variant. There was a small increase in risk when restricting the analysis to colorectal cancer with an HR of 3.5 (1.7-7.4). This increase in colorectal cancer risk was predominantly observed after age 60 years, 10 years after US Preventive Services Task Force guidelines recommend starting colonoscopies for the average population. Up to age 60 years, 2.6% of individuals with PMS2 pathogenic variants were diagnosed with colorectal cancer, closer to the general population (0.7%) than those with MLH1 (37.3%), MSH2 (28.9%), or MSH6 (6.7%) pathogenic variants. For 100,000 individuals screened for PMS2 , 854 additional colonoscopies would be performed, which would prevent or detect early 3.2 colorectal cancers. CONCLUSION This analysis across nine health systems highlights the clinical phenotypes of PMS2 pathogenic germline variants in the entire population.
Renal blood flow and progression to kidney failure in ADPKD
Nowak, Kristen L. , Ku, Elaine , Sarnak, Mark J, You, Zhiying, Bae, Kyongtae T, Chapman, Arlene, Perrone, Ronald D. , Torres, Vicente, Yu., A. Ershova, Chonchol, Michel, Torres, Vicente E , Nowak, Kristen L , Copeland, Timothy P. , You, Zhiying , Gitomer, Berenice Y , Abebe, Kaleab Z , Chapman, Arlene B. , Rahbari-Oskoui, Frederic F. , Chonchol, Michel

Mayo Clinic

Nephrology Dialysis Transplantation | March 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ndt/gfag059 | PMID 41811969 Get It

ABSTRACT Background A decrease in renal blood flow (RBF) precedes estimated glomerular filtration rate (eGFR) decline among patients with autosomal dominant polycystic kidney disease (ADPKD) and inversely associates with disease severity and progression. However, it is unknown whether RBF independently predicts progression to kidney failure in patients with ADPKD. Methods A total of 379 participants with early-stage ADPKD (mean age 36.6 ± 8.5 years; eGFR: 92.9 ± 17.1 ml/min/1.73 m2) who participated in the Halt Progression of Polycystic Kidney Disease Study A (HALT PKD A; NCT00283686) with baseline RBF (phase contrast magnetic resonance imaging) data were included in the primary analysis. Kaplan–Meier survival analysis and multivariate Cox proportional hazard models were used to determine the association of baseline RBF as a continuous and categorical variable with kidney failure risk (during the HALT study and subsequently linked to the US Renal Data System) over a median follow-up period of 13.1 years (interquartile range 7.5–14.5) (primary outcome). All-cause mortality was also considered as a competing risk (Fine and Gray method). The associations of RBF with eGFR slope and the change in height-adjusted total kidney volume (∆htTKV) were evaluated with linear and logistic regression models. Results The kidney failure incidence rate was the highest among those with the lowest RBF tertile {1.90 [95% confidence interval (CI) 1.31–2.78] versus 0.34 [95% CI 0.14–0.83] events/100 person-years in tertile 3}. In the fully adjusted model, the lowest RBF tertile was associated with a higher risk of progression to kidney failure [hazard ratio (HR) 3.19 (95% CI 1.05–9.67] versus the highest tertile]. The association of RBF with kidney failure risk was slightly attenuated in adjusted models. All associations remained similar when considering death as a competing risk [HR 0.82 (95% CI 0.67–1.00) per 100 ml/min/1.73 m2 higher RBF]. Higher RBF was associated with a slower eGFR decline and lower odds of rapid annual ∆htTKV. Conclusions Lower baseline RBF independently associates with a greater risk of progression to kidney failure in early-stage patients with ADPKD.
Real-time diagnosis of adult T-cell leukemia/lymphoma using HBZ RNA in situ hybridization
Amador, Catalina , Poveda, Julio , Mohammed, Ibraheem, Hyjek, Elizabeth , Gibson, Sarah, Horna, Pedro , Rech, Karen L. , Ramos, Juan C, Delma, Katiana S, Koepplin, Justin W. , Cassidy, Daniel P. , DiCaudo, David J. , Sokol, Lubomir , Iqbal, Javeed , Chapman, Jennifer R. , Gibson, Sarah E. , Bouska, Alyssa , Hyjek, Elizabeth , Gibson, Sarah E , Horna, Pedro , Rech, Karen , Cassidy, Daniel P , Sokol, Lubomir , Iqbal, Javeed , Chapman, Jennifer R , Amador, Catalina , Hyjek, Elisabeth, Ramos, Juan Carlos , Delma, Katiana S. , Moscinski, Lynn C.

Mayo Clinic

American Journal of Clinical Pathology | March 7, 2026 | Volume: 165 | Issue: 5 | Pages: No page available

10.1093/ajcp/aqag030 | PMID 42106909 Get It

Abstract Objectives Diagnosing adult T-cell leukemia/lymphoma (ATLL) remains challenging due to its clinical and histopathologic heterogeneity. While HTLV-1 serology is a key diagnostic criterion, it is often unavailable at the time of diagnosis and does not confirm viral integration in tumor cells. The HTLV-1–encoded HBZ RNA is a reliable diagnostic biomarker for ATLL. We evaluated the diagnostic performance of RNAscope in situ hybridization (ISH) for HBZ RNA in formalin-fixed, paraffin-embedded (FFPE) tissues to distinguish ATLL from other T-cell lymphomas. Methods HBZ ISH was evaluated in 72 cases, including 52 ATLLs and 20 non-ATLL T-cell lymphomas, to determine diagnostic sensitivity and specificity, interobserver agreement, interlaboratory reproducibility, and comparison with digital gene expression. Results This assay demonstrated 86.5% sensitivity and 100% specificity, with sensitivity improving to 97% when excluding bone marrow clot sections and FFPE blocks older than 5 years. Interobserver agreement among 3 pathologists was excellent (κ = 0.92, percent agreement: 94%). Interlaboratory reproducibility of HBZ ISH was high, with 93% to 95% concordance across these Clinical Laboratory Improvement Amendments–certified laboratories. HBZ RNA ISH–positive cases demonstrated significantly higher HBZ gene expression levels by digital gene expression profiling. Conclusions We established HBZ ISH as a reliable tissue-based surrogate for HTLV-1 infection in ATLL. This assay will enhance diagnostic accuracy, expedite definitive diagnosis, and improve patient selection for targeted therapies and clinical trials, particularly in regions with a high prevalence of HTLV-1.
Gastric fundal mucosal ablation followed by endoscopic sleeve gastroplasty in adults with obesity: a first-in-human two-phase pilot clinical trial
Gadi, Sanjay, Maselli, Daniel B. , Donnangelo, Lauren L., Wooley, Chase, Comer, Taylor, Casey, Shannon, Jain, Ankit , Jain, Aditya, Chapman, Christopher G., Bakheet, Nader , Badurdeen, Dilhana, Kumbhari, Vivek , McGowan, Christopher , Gadi, Sanjay R V , Wooley, Chase

Mayo Clinic

Endoscopy | February 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/a-2823-8603 | PMID 41760139 Get It

Abstract Endoscopic sleeve gastroplasty (ESG) facilitates 13.6%–16.2% total body weight loss (TBWL) at 12 months, but falls short of that seen with surgical vertical sleeve gastrectomy, in part owing to the retention of the gastric fundus. In adults with obesity, gastric fundal mucosal ablation (GFMA) reduces fasting plasma ghrelin (FPG), hunger, cravings, and accommodation. Combined GFMA-ESG could improve TBWL. This study aimed to evaluate the effectiveness and safety of sequential GFMA followed by ESG in adults with obesity, building on previously published 6-month results of GFMA alone. This was a prospective, first-in-human, two-phase clinical trial. Ten participants underwent GFMA, followed by ESG at month 6, and were followed for 12 months post-ESG (18 months total). GFMA was performed using hybrid argon plasma coagulation to lift and ablate the entire gastric fundal mucosa. ESG was performed using standard full-thickness endoscopic suturing of the gastric body. The primary end point was TBWL; secondary end points were safety and changes in FPG, maximum tolerated volume (MTV), and validated appetite questionnaires. Mean TBWL was 22.5% (SD 8.3%) at month 18. Hunger-related behaviors and eating self-efficacy showed sustained improvements. FPG was decreased at month 6 and returned toward baseline by month 18, while MTV remained suppressed. No serious adverse events occurred. Sequential GFMA-ESG is safe and induces substantial weight loss, reduced MTV of ingested nutrients, and improved behavioral measures. This combination approach builds on prior traditional ESG and GFMA-only results and may represent a promising advancement of endoscopic therapeutic options for weight loss.
Abstract PS3-07-23: Survivor plots for quantitated adjunctive statistically standardized ER, PgR, and HER2 in adjuvant postmenopausal breast cancer: Canadian Cancer Trials Group MA.27 trial of exemestane versus anastrozole
Chapman, J. W., Bayani, Jane , SenGupta, S., Bartlett, J. M. S., Piper, T., Quintayo, M. A., Virk, Shakeel , Goss, P. E., Ingle, J. N., Ellis, M. J., Sledge, G. W., Budd, G. T., Ansari, R. H., Tozer, Richard , D'Souza, D. P., Chalchal, H., Spadafora, S., Stearns, V., Perez, E. A., Gelmon, K. A., Whelan, T. J., Elliott, C., Shepherd, L. E., Chen, B. E., Taylor, K. J., Whelan, Timothy J. , Bartlett, J. M. S., Quintayo, Mary Anne , Ingle, J. N., Budd, G.T., Rabaglio, Manuela , D’Souza, David , Chalchal, H., Stearns, Vered , Shepherd, Lois E. , Chen, B. E., Taylor, K. J., Whelan, Timothy J

Mayo Clinic

Clinical Cancer Research | February 20, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: PS3-07-23-PS3-07-23

10.1158/1557-3265.sabcs25-ps3-07-23 Get It

Abstract Background: Survivor plots permit adjustment by baseline demographics and clinical characteristics; log-normal survival analysis may be more robust than a Cox model under departures from model assumptions. We depicted distant disease-free survival (DDFS) for statistically standardized quantitated ER, PgR, and HER2. Methods: We utilized CCTG MA.27 (NCT00066573), an adjuvant phase III trial of exemestane versus anastrozole in postmenopausal women with ER+ and/or PgR+ tumours. IHC ER, PgR, and HER2 HSCORE were centrally assessed by machine image quantitation, and statistically standardized to mean of 0, standard deviation (SD) of 1 following Box-Cox variance stabilization transformations of square for ER, natural logarithm (ln) and square root for PgR, and ln for HER2. For the ln transformation, 0.1 was added to 0 HSCOREs for a stable transformation. The primary endpoint was DDFS at the longest trial follow-up of 4.1 years. For log-normal survival analysis, ln(time) is a linear function of covariates and had a normal distribution; the Cox models were log-linear for covariates. Survival was depicted with log-normal and Cox survivor plots adjusted at the means of age, T and N stage, grade, lymphovascular invasion, treatment, and baseline patient demographics. We examined ER and PgR ASCO/CAP cut-points at (0; >0), HER2 cut-points at (IHC 0, 0 stain; IHC 0, (0,10%] stain; IHC 1+; IHC 2+; IHC 3+), and ER/PgR/HER2 standardized cut-points at standard deviations about mean of 0 (<-1; (-1,0]; (0,1]; >1). P was based on the likelihood ratio criterion (∼Χ2 (1)) for the addition of ER/PgR/HER2 to the model of baseline covariates, and had nominal significance if P<0.05. Log-normal and Cox multivariable regressions with unstandardized and standardized categorical, and continuous, ER, PgR, and HER2 were adjusted by baseline covariates; 2-sided Wald tests had nominal significance if P<0.05. Results: Of 7576 MA.27 patients, 2325 patients had quantitated image analysis assessments for ER, PgR, and HER2; 113 of 2325 (4.9%) patients experienced a DDFS event during follow-up. Multivariable log-normal survival analysis indicated DDFS was significantly longer for patients with T1 (p=0.01), N0 (p=.002), and grade 1/2 tumors (p=0.01); similar significance levels were found with a Cox model. Log-normal survivor plots were smooth, while Cox survivor plots were step-wise discontinuous at events. Adjusted log-normal survivor plots indicated similar 5-year DDFS for patients by standardized ER categories (p=0.43): 95.4% for those with ER <-1.0 (n=401); 95.8%, for (-1.0,0.0] (n=737); 96.1%, for (0.0,1.0] (n=737); and 96.4%, for >1.0 (n=450). The log-normal standardized PgR survivor plots indicated patients had significantly different 5-year DDFS (p<.001) by categories, with both ln and square root transformations of HSCORE: with a ln transformation, 93.7% for <-1.0 (n=607); 95.4%, for (-1.0,0.0] (n=390); 96.8%, for (0.0,1.0] (n=826); and 97.8%, for >1.0 (n=502). Patients had similar 5-year DDFS by standardized HER2 categories (p=0.71): 96.2% for <-1.0 (n=83); 96.0%, for (-1.0,0.0] (n=1201); 95.9%, for (0.0,1.0] (n=527); and 95.7%, for >1.0 (n=514). In full fit multivariable log-normal survival analyses, DDFS was not significantly different for ER (p=0.51-0.89) and HER2 (p=0.12-0.98); higher PgR was associated with significantly better DDFS (p=0.01 to <.001). Adjusted Cox survival analyses had similar results. Conclusions: Survivor plots adjusted for baseline demographic and clinical characteristics provided similar indications of significance for standardized ER, PgR, and HER2 as those seen in multivariable models with both log-normal and Cox survival analyses. Higher PgR was associated with significantly better DDFS. Citation Format: J. W. Chapman, J. Bayani, S. SenGupta, J. M. S. Bartlett, T. Piper, M. A. Quintayo, S. Virk, P. E. Goss, J. N. Ingle, M. J. Ellis, G. W. Sledge, G. T. Budd, M. Rabaglio, R. H. Ansari, R. Tozer, D. P. D'Souza, H. Chalchal, S. Spadafora, V. Stearns, E. A. Perez, K. A. Gelmon, T. J. Whelan, C. Elliott, L. E. Shepherd, B. E. Chen, K. J. Taylor. Survivor plots for quantitated adjunctive statistically standardized ER, PgR, and HER2 in adjuvant postmenopausal breast cancer: Canadian Cancer Trials Group MA.27 trial of exemestane versus anastrozole [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS3-07-23.
Relationship between Total Kidney Volume and eGFR in Autosomal Dominant Polycystic Kidney Disease
Asl, Yu, Parker, C., Golzarri‐Arroyo, Lilian , Landsittel, Douglas P., Garg, Rekha, Lee, Edmund C. , Chapman, Arlene B., Rahbari-Oskoui, Frederic F. , Mrug, Michal , Harris, Peter, Torres, Vicente, Harris, Peter C. , Yu, Alan S.L. , Yu, Alan S L , Parker, Chelsie , Chapman, Arlene B. , Harris, Peter C , Torres, Vicente E , Rahbari-Oskoui, Frederic F , Landsittel, Douglas P.

Mayo Clinic

Clinical Journal of the American Society of Nephrology | February 13, 2026 | Volume: 21 | Issue: 5 | Pages: 833-840

10.2215/cjn.0000000992 | PMID 41686506 Get It

Key Points In autosomal dominant polycystic kidney disease, there is a linear relationship between the log-transformed total kidney volume and eGFR. There is a predictable change in the rate of eGFR decline with reduction in kidney growth rate. This framework can be used to determine treatment effect to support accelerated approval of drugs for polycystic kidney disease. Background Total kidney volume (TKV) is accepted by the US Food and Drug Administration as a surrogate end point that is reasonably likely to predict clinical benefit in autosomal dominant polycystic kidney disease and the most commonly used response biomarker for proof-of-concept intervention trials. However, the magnitude of treatment effect on TKV that would be predictive of a meaningful improvement in a clinical outcome, such as eGFR, is unknown. Inference of this from observational studies has previously been approached by examining interindividual variance in the relationship between TKV and GFR slopes over time. Methods We developed a novel approach to modeling the intraindividual relationship between TKV and eGFR. Patients from the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease and Halt Progression of Polycystic Kidney Disease Study A dataset were stratified by Mayo Imaging Class (MIC). Linear mixed models were fitted to eGFR with a fixed effect of log(TKV) and random intercepts, and the average slope within each MIC was estimated. Results We found that within each MIC, there is a consistent, linear relationship between log(TKV) and eGFR. The model predicts that within classes 1C–1E, for each 1% point per year reduction in TKV growth rate, the rate of eGFR decline would be reduced by 0.40–0.52 ml/min per 1.73 m 2 per year. Conclusions We have developed a new model that provides a framework for defining the magnitude of treatment effect on TKV that would support accelerated approval of a drug for autosomal dominant polycystic kidney disease. Podcast This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2026_05_18_CJASNMay.21.5.51820.mp3